PDF(Pubmed)
Abstract：
UNASSIGNED: Pain is the prominent feature of sickle cell disease (SCD) and negatively affects quality of life. Delivery of pain management programmes (PMPs) has been suggested in clinical guidelines for pain management in SCD; however, further evidence of the feasibility and effectiveness of PMPs in this population is needed. This study explored the feasibility of delivering a sickle cell pain management programme (SCPMP) for adults within a haemoglobinopathies service.
UNASSIGNED: A single arm, repeated-measures observational design was used to determine feasibility of delivering the SCPMP at one study site. Primary feasibility outcomes were recruitment, completion of treatment and outcome measures, satisfaction, credibility and acceptability to participants. Secondary feasibility outcomes were treatment outcomes and processes, frequency of vaso-occlusive crisis (VOC) and healthcare utilisation.
UNASSIGNED: Four of five feasibility criteria were met. Annual recruitment of eight participants to a SCPMP was not achieved. Twenty-nine people began a SCPMP during the study period. Twenty-five (86.2%) participants attended ≥5/8 sessions and 21(84%) programme completers provided all end of programme questionnaires. Mean scores of >7 on ten-point scales were seen across satisfaction and credibility questions. At least moderate (Hedges g >0.5) effect sizes were seen in pre-post SCPMP measures of pain interference, anxiety, depression, self-efficacy, pain-related worry and acceptance. A small (Hedges g 0.4) effect size was seen in HRQoL. Following SCPMP attendance, mean frequency of self-reported VOC and hospital admissions reduced.
UNASSIGNED: This study suggests that, given an adequate source of referrals, a SCPMP is feasible to deliver and appears acceptable and credible to participants. Exploration of influences on recruitment, such as barriers to group interventions, would be illuminating, prior to investigating feasibility of an adequately powered randomised-controlled trial.
UNASSIGNED: A single arm, repeated-measures observational design was used to determine feasibility of delivering the SCPMP at one study site. Primary feasibility outcomes were recruitment, completion of treatment and outcome measures, satisfaction, credibility and acceptability to participants. Secondary feasibility outcomes were treatment outcomes and processes, frequency of vaso-occlusive crisis (VOC) and healthcare utilisation.
UNASSIGNED: Four of five feasibility criteria were met. Annual recruitment of eight participants to a SCPMP was not achieved. Twenty-nine people began a SCPMP during the study period. Twenty-five (86.2%) participants attended ≥5/8 sessions and 21(84%) programme completers provided all end of programme questionnaires. Mean scores of >7 on ten-point scales were seen across satisfaction and credibility questions. At least moderate (Hedges g >0.5) effect sizes were seen in pre-post SCPMP measures of pain interference, anxiety, depression, self-efficacy, pain-related worry and acceptance. A small (Hedges g 0.4) effect size was seen in HRQoL. Following SCPMP attendance, mean frequency of self-reported VOC and hospital admissions reduced.
UNASSIGNED: This study suggests that, given an adequate source of referrals, a SCPMP is feasible to deliver and appears acceptable and credible to participants. Exploration of influences on recruitment, such as barriers to group interventions, would be illuminating, prior to investigating feasibility of an adequately powered randomised-controlled trial.
摘要：
■疼痛是镰状细胞病（SCD）的突出特征，对生活质量产生负面影响。在SCD疼痛管理的临床指南中建议实施疼痛管理计划（PMPs）；然而，需要进一步证据证明PMPs在该人群中的可行性和有效性.这项研究探讨了在血红蛋白病服务中为成年人提供镰状细胞疼痛管理计划（SCPMP）的可行性。
■单臂，重复测量观察性设计用于确定在一个研究地点交付SCPMP的可行性.主要的可行性结果是招募，完成治疗和结果测量，满意,参与者的可信度和可接受性。次要可行性结果是治疗结果和过程，血管闭塞危象（VOC）的频率和医疗保健利用。
■符合五个可行性标准中的四个。没有实现每年招募八名参与者参加SCPMP。在研究期间，有29人开始了SCPMP。25名（86.2％）参与者参加了≥5/8次会议，21名（84％）计划完成者提供了所有计划结束问卷。在满意度和可信度问题上，10分制的平均得分>7。在SCPMP治疗前的疼痛干预措施中，至少可以看到中等（Hedgesg>0.5）的效应大小，焦虑,抑郁症,自我效能感,与疼痛相关的担忧和接受。在HRQoL中观察到小的(Hedgesg0.4)效应大小。SCPMP出席后，自我报告VOC的平均频率和住院率降低。
■这项研究表明，如果有足够的推荐来源，SCPMP是可行的，并且对于参与者来说似乎是可以接受和可信的。探索对招聘的影响，例如团体干预的障碍，会很有启发性，在研究足够有效的随机对照试验的可行性之前。
■单臂，重复测量观察性设计用于确定在一个研究地点交付SCPMP的可行性.主要的可行性结果是招募，完成治疗和结果测量，满意,参与者的可信度和可接受性。次要可行性结果是治疗结果和过程，血管闭塞危象（VOC）的频率和医疗保健利用。
■符合五个可行性标准中的四个。没有实现每年招募八名参与者参加SCPMP。在研究期间，有29人开始了SCPMP。25名（86.2％）参与者参加了≥5/8次会议，21名（84％）计划完成者提供了所有计划结束问卷。在满意度和可信度问题上，10分制的平均得分>7。在SCPMP治疗前的疼痛干预措施中，至少可以看到中等（Hedgesg>0.5）的效应大小，焦虑,抑郁症,自我效能感,与疼痛相关的担忧和接受。在HRQoL中观察到小的(Hedgesg0.4)效应大小。SCPMP出席后，自我报告VOC的平均频率和住院率降低。
■这项研究表明，如果有足够的推荐来源，SCPMP是可行的，并且对于参与者来说似乎是可以接受和可信的。探索对招聘的影响，例如团体干预的障碍，会很有启发性，在研究足够有效的随机对照试验的可行性之前。
